YGYulia V. Gorbunova

Yulia V. Gorbunova

*This is an algorithmically generated author record based on publicly available information.

Yulia V. Gorbunova has a total of 82 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Logistical parameters of goods as an object of optimization of warehouse accounting and operational processes

    by Elizaveta V. Pavlova, Павлова Елизавета Валерьевна, Denis V. Kurkin, Куркин Денис Владимирович, Yulia V. Gorbunova, Горбунова Юлия Васильевна, Olga V. Marincheva, Маринчева Ольга Викторовна, Dmitry A. Bakulin, Бакулин Дмитрий Александрович, et al.

    Introduction. Optimization of warehouse accounting and operational processes is an important area for improving the efficiency of pharmaceutical logistics. The aim of the study was to investigate operational processes and the warehouse accounting system for potential optimization. Materials and methods. The object of the study was the processes of managing the logistical parameters of goods at the pharmaceutical warehouse of FM Logistic JSC while servicing the International Committee of the Red Cross. Issues of management, economics, law, and digitalization Results. It was demonstrated that the transition from a paper-based information card to direct data entry using a handheld data terminal in the warehouse management system reduced the processing time per item from 5 min 49 s to 1 min 51 s, that is, by 68.2%. Discussion. The proposed approach may be applied in warehouses with a broad and dynamically changing assortment to improve the quality of master data management. Conclusion. Effective master data management makes it possible to improve subsequent warehouse processes, such as product slotting, generation of order picking tasks, calculation of the number, volume, and weight of cargo units, and transport planning for the delivery of prepared orders.

  • Разработка и валидация методики количественного определения метформина гидрохлорида и таурина в комбинированной лекарственной форме методом ВЭТСХ

    by Константин Сергеевич Бакулин, Екатерина Сергеевна Просандеева, Владислав Валентинович Сепп, Санджи Викторович Убушаев, Юлия Васильевна Горбунова, Денис Владимирович Куркин

    Комбинация метформина и таурина актуальна для терапии сахарного диабета 2 типа в связи с синергией фармакологических эффектов. Для обеспечения качества разрабатываемой лекарственной формы с пролонгированным высвобождением требуется простой и надежный аналитический метод для одновременного количественного определения обоих компонентов. Цель работы — разработка и валидация метода идентификации и количественного определения метформина гидрохлорида и таурина в комбинированной лекарственной форме пролонгированного действия методом высокоэффективной тонкослойной хроматографии (ВЭТСХ). Использовали пластины HPTLC Merck Silicagel 60 F254, подвижная фаза: этанол — хлороформ — 15 % раствор ацетата аммония, 6:3:2 (об./об./об.). Метформин детектировали при 239 нм до дериватизации, таурин — при 487 нм после обработки пластинки 0,01 % раствором нингидрина в этаноле и нагрева при 75 °C. Валидация проведена по специфичности, линейности, точности, прецизионности, пределу количественного определения и робастности. Оптимизированы условия хроматографирования, подобрана подвижная фаза, обеспечивающая эффективное разделение метформина и таурина (Rf метформина — 0,34, таурина — 0,24), а также метод дериватизации (автоматическое погружение в 0,01 % нингидрин). Метод валидирован в диапазоне 0,03125 – 0,5 мг/мл. Линейность подтверждена по 9 аналитическим сериям (для метформина R2 = 0,992 – 0,999, SDV ≤ 3,0 %; для таурина R2 = 0,896 – 0,999, SDV ≤ 3,7 %). Точность (восстановление 97,8 – 105,2 % для метформина при 0,25 – 0,0625 мг/мл; 99,4 – 110,5 % для таурина при 0,25 – 0,0625 мг/мл) и промежуточная прецизионность не превышали 6,67 % при 0,0625 мг/мл и 12,87 % при 0,03125 мг/мл, что приемлемо для нижнего предела диапазона LOQ = 0,03125 мг/мл. Растворы стабильны 24 ч. Метод применим для анализа разрабатываемой формы. Разработанная методика ВЭТСХ проста, экономична, позволяет одновременно определять метформин и таурин в одной пробе. Она может быть использована для рутинного контроля качества и исследований in vitro на всех этапах разработки и производства комбинированных препаратов на основе этих субстанций.

  • Original drug products approved by the Food and Drug Administration (Center for Drug Evaluation and Research) in 2025

    by D. V. Kurkin, N. A. Osadchenko, D. A. Galkina, D. A. Bakulin, Yu. G. Ustyakina, S. A. Voskresensky, A. R. Makarova, O. V. Shatalova, A. V. Strygin, V. I. Petrov, et al.

    The annual review of new drugs approved by the FDA is an important tool for analyzing current trends in pharmacology and medicine, reflecting progress in the treatment of complex diseases, including oncological pathologies, orphan diseases, and infectious processes. The article aims to inform medical specialists and pharmacologists about current trends in the development and registration of innovative medicinal products in 2025. The aim. To summarize and systematize data on the latest medicinal products launched in 2025, and to analyze their mechanisms of action. Materials and methods. The presented data are taken from open sources and supplemented by the results of individual studies aimed to the investigate new mechanisms and approaches in therapy. The main list of new medicines and introductory information about them are taken from the report of the Food and Drug Administration (FDA) — "Novel Drug Approvals for 2025. Results. In 2025, the FDA approved 46 drugs, of which 31 were small molecules and 15 were macromolecules. Among the drugs in the first group, 11 (24 % of all new drugs and 35 % of all new small molecules) are used in oncology, 2 are immunotropic, and 2 are for cardiology. The majority (16 drugs) belong to miscellaneous drug groups. Among biologicals, the largest portion consisted of monoclonal antibodies for the treatment of non-oncological diseases — 6 (13 % of all and 40 % of biologicals) and monoclonal antibodies for the treatment of oncological diseases — 5 (11 % of all and 33 % of biologicals). Nucleic acid-based drugs and protein molecules, excluding antibodies, accounted for 3 (7 % of all and 20 % of biologicals) and 1 (2 % of all and 7 % of biologicals) respectively. Conclusion. The significant proportion of biopharmaceuticals among newly registered drug products in 2025 highlights the dynamic development of the pharmaceutical industry and its focus on personalized medicine and biotechnology. Therapy based on mAbs interacting with receptors, as well as immunotherapy based on newly discovered mechanisms of anti-tumor immunity, occupies a substantial part of the structure of original drugs. The search for new rational antibiotic combinations remains relevant. Small molecules still constitute the largest share of the original drug market, among which drug substances — ligands of new targets and oligonucleotide sequences are emerging. This review is compiled for medical specialists and pharmacologists to familiarize them with current trends in the registration of original drugs and in the therapy of malignant neoplasms, as well as orphan diseases.

  • Open Access

    Review of medicines approved by the Food and Drug Administration from 2012 to 2024

    by D. V. Kurkin, N. A. Osadchenko, D. A. Bakulin, E. I. Morkovin, S. A. Voskresenskiy, D. V. Maltsev, M. O. Maltseva, Yu. V. Gorbunova, O. V. Marincheva, V. I. Zvereva, et al.

    The aim . To describe the key characteristics of medical products approved by the Food and Drug Administration (FDA) and released by pharmaceutical companies from 2012 to 2024. Materials and methods. The analysis is based on data from FDA publications related to the approval of medical products from 2012 to 2024. The products were systematized by year, pathway and reason for approval, nature of the active substance (synthetic, semi-synthetic, natural or biological) and target disease (indication for use) in accordance with the codes of the Anatomical Therapeutic Chemical (ATC) classification. Results . During the analyzed period, the FDA approved a significant number of medicines, while maintaining a stable proportion of small molecules with a significant upward trend in the number of approved biologicals (monoclonal antibodies, CAR-T, siRNA, gene therapy, etc.). The largest proportion was accounted for by antitumor drugs and immunomodulators (group L according to ATC), demonstrating steady growth with projected growth in the future. Interest in drugs for the treatment of metabolic disorders and diseases of the nervous system remained steadily high, with the emergence of innovative therapeutic approaches. A gradual increase in the number of repositionings and extensions of indications was noted. The COVID-19 pandemic did not have a significant impact on the overall structure of approvals, and only two specific medicines for the treatment of COVID-19 were approved. There has been an increase in approvals for orphan diseases and the emergence of innovative therapeutic approaches: gene therapy, RNA interference, cell technologies, and bispecific antibodies. Conclusion. In the period from 2012 to 2024, the pharmaceutical industry has seen a fundamental shift towards biotechnological development methods, personalized medicine, and targeted therapy. During the period under review, the proportion of small molecule approvals remained fairly stable, but a steady (compared to previous periods) increase in the number of biotechnology product approvals (monoclonal antibodies, gene and RNA therapy) can be noted. The largest increase was noted in class L (antitumor drugs and immunomodulators), which reflects the focus of global pharmaceutical companies on the fundamental study and discovery of pharmacotherapy opportunities in the oncology and immunity. It is necessary to note the trend towards the development of drugs for the treatment of rare (orphan) diseases. In the field of therapy for metabolic disorders, during the specified period, drugs were approved that revolutionized understanding of an entire cluster of diseases and approaches to therapy, and a new standard of therapy was formed due to SGLT2 inhibitors and agonists of the incretin system receptors, including molecules with a multi-targeted effect. The COVID-19 pandemic led to a limited number of drug approvals for the treatment of this infection but thanks to it, the “door” to the development of new generation vaccines has been opened, which are largely fundamentally different from those currently existing. The discovery of new means to combat infectious agents of various nature (bacteria, protozoa, viruses, fungi, and parasites) is also one of the priority goals of pharmaceutical companies, as evidenced by a significant proportion of approvals of drugs with a similar effect. In terms of “reasons for registration,” the main share fell on original drugs; the contribution of new combinations and dosage forms was at its peak in the middle of the period and then decreased. Due to the expiration of patent protection for many drugs and the accumulation of data on their effects in the post-marketing period, a gradual increase in the number of repositionings and extensions of indications can be logically noted.


  • Comparative study of the neuroprotective effects of the drug Cytoflavin and citicoline in a rats model of hemorrhagic stroke

    by A.L. Kovalenko, A.YU. Petrov, G.A. Plisko, D.V. Kurkin, D.A. Bakulin, Yu.V. Gorbunova, N.O. Osadchenko, K.V. Lenskaya

    Objective. To compare the neuroprotective effects of Cytoflavine (CF) and citicoline (CC) in a rat model of hemorrhagic stroke (HS). Material and methods. The study was conducted on male Wistar rats. HS was induced by the injecting of autologous blood into brain tissue. Drugs CF and CC were administered in parenteral (10 days) and oral (25 days) forms. The experiment concluded with a 14-day post-treatment period. Neurological deficits were assessed after each treatment period, and brain tissue edema was measured immediately after the completion of both parenteral and oral treatments and again after 14 days of drug discontinuation. A series limited to a 10-day intravenous treatment with CF was created to compare the efficacy of single and combined treatment regimens. Results. HS stroke led to the development of significant neurological deficits. The greatest improvement was observed in the groups receiving oral treatments with CF and CC, which demonstrated pronounced neuroprotective effects and accelerated recovery of impaired functions, with some differences between the groups. The 10-day intravenous administration of CF and CC resulted in a comparable significant reduction in the severity of neurological deficits related to sensorimotor dysfunction. However, substantial recovery of cognitive function required continuation of oral treatment for 25 days. At the end of the oral treatment phase, edema severity in the affected hemisphere was comparable between both groups and significantly lower than in the placebo group. The therapeutic effect of CF (in terms of neurological deficit and brain tissue edema), in a combined administration regimen, persisted 14 days after discontinuation of treatment, in contrast to CC. In an additional series, where CF treatment was limited to a 10-day intravenous course, the anti-edema effect did not remain significant after the 14-day treatment cessation, with notable differences from the untreated group observed only in motor activity levels. Conclusion. The comparative study of the neuroprotective effects of CF and CC in a rat model of HS revealed that both drugs significantly reduced brain edema and neurological deficits related to sensorimotor and cognitive impairments. CC showed a slight psychostimulatory effect and a shorter duration of action after treatment cessation, while CF exhibited a longer-lasting effect on brain tissue edema, cognitive, and sensorimotor functions after discontinuation. The separate series with only 10-day intravenous CF administration was insufficient to achieve a stable therapeutic effect, suggesting that the continuation of CF treatment with oral forms is required to maintain long-term benefits in the context of experimental HS in rats.

  • Open Access

    Dynamics of turnover of sugar-lowering drugs in the retail segment of the pharmaceutical market from 2020 to 2024

    by D. V. Kurkin, E. V. Makarova, V. I. Zvereva, A. R. Makarova, D. A. Bakulin, O. V. Marincheva, Yu. V. Gorbunova, Yu. A. Kolosov, I. S. Krysanov, K. N. Koryanova, et al.

    A significant part of patients with diabetes purchase sugar-lowering drugs (SLDs) on their own in retail pharmacy chains, and the market trends they generate represent an urgent area for this study.The aim. To study the turnover of hypoglycemic drugs, including insulins, in the commercial sector of the pharmaceutical market of the Russian Federation (RF) for 2020–2024.Materials and methods. The data presented in this article is based on a periodic retail audit conducted by the biotech company IQVIA. The period of 5 years (2020–2024) was covered. Data collection covered 33,613 commercial pharmacies in all regions of the RF (about 43% of pharmacies).Results. In the period from 2020 to 2023, a relatively stable increase in the volume of SLDs purchases was revealed, with small fluctuations, while in 2024 a significant leap in consumption was recorded, both in quantitative (packages) and in value (rubles) terms. During the entire monitoring period, the total volume of SLDs and insulin purchases in the retail market segment increased by more than 1.2 times, from 41.98 million packages in 2020 to 51.70 million in 2024. At the same time, the total procurement budget (at wholesale prices) increased by more than 2 times — from 19.40 to 41.57 billion rubles. The average price per package has also increased significantly, from 462 rubles in 2020 to 923 rubles in 2024, an increase of 1.7 times, reflecting significant inflation in the commercial pharmaceutical sector. In general, the Russian pharmaceutical market offers all variants of modern innovative hypoglycemic drugs (dipeptidyl peptidase-4 inhibitors [iDPP4], sodium-glucose cotransporter 2 inhibitors [iSGLT2], glucagon-like peptide-1 receptor agonists [arGPP-1]), which, according to general trends, demonstrate a steady increase in turnover. Older and less effective sulfonylureas and their combinations with metformin still occupy a significant market share. arGPP-1 group showed the greatest growth in quantity (11 times) and value (5 times), mainly due to the entry of Russian semaglutide analogues into the market. Government measures and investments in import substitution have led to a significant increase in the share of Russian drugs in purchases. Despite the positive dynamics of Russian production, import substitution in the SLDs segment has not achieved complete success and accounts for less than half of the turnover of hypoglycemic drugs.Conclusion. The growth of SLDs consumption in the retail segment of the RF in 2020–2024 has been revealed, especially due to the innovative drugs arGPP-1 and iNGLT2. Despite maintaining the leading position of metformin, the consumption structure is shifting towards more expensive schemes. The increase in the total procurement budget and the average package price highlights the need to expand preferential security programs. Import substitution has increased significantly over the indicated period, however, the share of domestic drugs is still less than half of the turnover.


  • Open Access

    Original drugs approved by the Food and Drug Administration (Center for Drug Evaluation and Research) in 2024

    by D. V. Kurkin, N. A. Osadchenko, A. R. Makarova, D. A. Galkina, D. A. Bakulin, O. V. Shatalova, A. V. Strygin, V. I. Petrov, O. V. Marincheva, Yu. V. Gorbunova, et al.

    The U.S. Food and Drug Administration (FDA), in particular the Center for Drug Evaluation and Research (CDER), plays a key role in ensuring the safety, efficacy, and innovation of medicines entering the U.S. market, and then the world. The annual review of new medicines approved by the FDA is an important tool for analyzing current trends in pharmacology and medicine, reflecting progress in the treatment of complex diseases, including cancers, orphan diseases, and infections. The review is compiled to familiarize medical specialists and pharmacologists with current trends in the registration of original medicines and in the therapy of malignant neoplasms, orphan diseases.The aim. To summarize and systematize data on the newest medicines that entered the market in 2024, as well as to analyze the mechanisms of their action. The article aims to inform medical specialists and pharmacologists about current trends in the development and registration of innovative medicines in 2024.Materials and methods. The presented data are taken from open sources and supplemented with the results of individual studies on new mechanisms and approaches in therapy. The main list of new drugs and introductory information about them are taken from the FDA report “Novel Drug Approvals for 2024”. Data on medicine prescriptions, as well as information on the mechanism of action, are taken from published summary of product characteristics (SmPC) published on this resource, as well as from the Drugs.com website. To describe previously registered medicines for which a new indication is presented, Drugs.com reports were also used. Structural formulas of drugs are taken from the PubChem resource. In case of the absence of structural formula, data from their SmPC or third-party resources, such as Drugbank, were used. The search for literature data on fundamental studies relating to the mechanisms of action of the presented medicines was carried out in the PubMed, ResearchGate, Google Scholar and elibrary.ru databases.Results. A statistical analysis of registrations, the dynamics of changes in the shares of various types of medicines and basic data on new original drugs registered by CDER are presented. In 2024, the FDA registered 50 original medicines, among which 48% contain a “first-in-class” molecule as an active substance. Small molecules include active substances — 60%, and biopharmaceuticals — 34% (the remaining 6% are imaging agents). At the same time, monoclonal antibodies (mAb) of antitumor and anti-inflammatory action occupy a larger share among biopharmaceuticals.Conclusion. The large proportion of biopharmaceuticals among those newly registered in 2024 emphasizes the dynamic development of the pharmaceutical industry and its focus on personalized medicine and biotechnology. Therapy based on mAbs interacting with receptors, as well as immunotherapy based on newly discovered mechanisms of antitumor immunity, occupies a separate part in the structure of registered original medicines. The search for new rational combinations of antibiotics remains relevant. Most of the original drug market is still made up of small molecules, among which there are medicines — ligands of new targets and oligonucleotide sequences.


  • Targeting NMDAR/AMPAR: a promising pharmacotherapeutic approach for depressive disorders

    by D.V. Kurkin, E.I. Morkovin, D.A. Bakulin, Yu.V. Gorbunova, O.V. Ivanova, E.V. Pavlova, V.I. Zvereva, M.A. Dzhavakhyan, I.S. Krysanov, Yu.A. Kolosov, et al.

    Depression is a leading cause of disability and reduced work capacity worldwide. The monoamine theory of the pathogenesis of depression has remained dominant for many decades, however, drugs developed on its basis have limited efficacy. Exploring alternative mechanisms underlying this pathology could illuminate new avenues for pharmacological intervention. Targeting glutamatergic pathways in the CNS, particularly through modulation of NMDA and AMPA receptors, demonstrates promising results. This review presents some existing drugs with glutamatergic activity and novel developments based on it to enhance the efficacy of pharmacotherapy for depressive disorders.

  • Open Access

    Fixed ratio combinations GLP-1RA and basal insulin: literature review

    by D. V. Kurkin, D. A. Bakulin, E. I. Morkovin, A. V. Strygin, Ju. V. Gorbunova, E. V. Volotova, A. I. Robertus, I. E. Makarenko, V. B. Saparova, R. V. Drai, et al.

    The progressive nature of type 2 diabetes mellitus leads to the need for insulin therapy in a significant proportion of patients. Very often start of insulin therapy in type 2 diabetes mellitus (T2DM) is associated with weight gain and a significant increase of hypoglycemia’s risk. However, innovative options, such as fixed ratio combinations of glucagon-like peptide 1 receptor agonists (GLP-1RA) and basal insulin, minimize weight gain and hypoglycemia risks and allow a greater proportion of patients to achieve individual glycemic control goals without compromising safety parameters. This review includes a description of the randomized clinical trials, as well as the results of real clinical practice of the use of two currently existing fixed ration combinations of GLP-1RA and basal insulin — iDegLira and iGlarLixi.


  • Open Access

    Methodological and regulatory aspects of pharmaceutical development of biological products

    by D. V. Kurkin, E. I. Morkovin, D. A. Bakulin, А. В. Заборовский, I. E. Makarenko, R. V. Drai, A. G. Solodovnikov, V. I. Petrov, K. N. Koryanova, N. A. Lycheva, et al.

    The aim of the work was to conduct an analysis of the current state and current trends in the approval of drugs, as well as some aspects of the methodology for their development based on biological molecules and registration.Materials and methods. The material for the analysis was taken from the abstract databases of PubMed, Google Scholar and e-library.ru. The search was carried out using publications for the period from 2008 to 2023, the keywords were as follows: “biologicals”, “new drug approval”, “drug authorization”, “drug development”, “biosimilar”, taking into account various spellings.Results. Over the past 15 years, scientists have been observing revolutionary trends and processes in the field of the drug development, especially biopharmaceuticals. Significant advances have been made in gene, immune and cell therapies, resulting in the approval of such drugs more than doubling over the past ten years. The development of biological drugs includes the identification and testing of molecular targets and requires a deep understanding of the structure and functioning of the polypeptides involved in the development of the effect. The features of these active pharmaceutical substances are a high molecular weight, a complex three-dimensional structure and a high immunogenic potential. Preclinical and clinical studies of biologics have unique challenges. Selecting appropriate animal species, understanding the immunogenicity, and assessing pharmacodynamics and toxicological properties require a multilevel, detailed approach. The article discusses the regulatory framework under which these drugs are registered, summarizing the guidelines provided by international organizations such as the International Council for Harmonization and various national agencies.Conclusion. The analysis highlights the current advances and prospects in the development of biologics, highlighting their key role in future transformations in the treatment of rare diseases and oncology, approaching the era of personalized medicine. Monitoring the development directions and technological approaches, as well as the commitment to global methodological and regulatory aspects can become a catalyst in the development of the Russian pharmacology.